StockData

BioLineRx vs XTL Biopharmaceuticals

BLRX and XTLB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BLRX and XTLB compare

BioLineRx scores higher on the StockData Score (3 against 0 for XTL Biopharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBLRXXTLB
Size and price
Share price$1.12$1.62
Change, 1 year−65.3%−56.0%
Change, 5 years−98.9%−86.5%
Beta (5Y)1.561.14
Employees203
StockData Score
Total score3 (better)0
Valuation score00
Growth score1 (better)0
Performance score00
Health score2 (better)0
Dividend score00
Growth
Revenue growth (TTM)−95.9%–
Profitability
Gross margin80.5%–
Operating margin−872%–
FCF margin−686%–
Return on invested capital−59.7%–
Financial health
Debt / equity0.33–
Interest coverage−8.0×−6.3× (better)
Current ratio1.20–
Ownership
Held by institutions0.00%0.00%
Held by insiders0.39%0.00%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.